Concord Biotech Limited (NSE:CONCORDBIO)
India
· Delayed Price · Currency is INR 2,068.50
-61.90 (-2.91%)
Jun 12, 2025, 3:30 PM IST
Concord Biotech Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 |
| Net Income | 3,716 | 3,081 | 2,401 | 1,749 | 2,349 | Upgrade
|
| Depreciation & Amortization | 543.74 | 535.43 | 538.94 | 498.96 | 273.69 | Upgrade
|
| Other Amortization | - | 0.49 | 1.39 | 1.55 | 1.54 | Upgrade
|
| Loss (Gain) From Sale of Assets | 2.25 | -0.12 | 0.94 | 0.34 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -222.64 | -140.65 | -37.17 | -52.3 | -69.86 | Upgrade
|
| Loss (Gain) on Equity Investments | 13.22 | -33.71 | -19.59 | 36.38 | 4.49 | Upgrade
|
| Provision & Write-off of Bad Debts | 17.84 | 6.69 | 0.92 | -3.46 | 4.59 | Upgrade
|
| Other Operating Activities | 81.91 | 17.31 | 96.59 | 71.19 | -7.52 | Upgrade
|
| Change in Accounts Receivable | -1,708 | -786.6 | -430.97 | -527.69 | 65.01 | Upgrade
|
| Change in Inventory | -317.13 | 43.61 | -172.27 | -415.12 | -423.77 | Upgrade
|
| Change in Accounts Payable | 220.89 | -112.87 | 98.81 | 365.35 | -225.1 | Upgrade
|
| Change in Other Net Operating Assets | 96.54 | 44.06 | -18.42 | 356.91 | -303.77 | Upgrade
|
| Operating Cash Flow | 2,445 | 2,655 | 2,460 | 2,081 | 1,668 | Upgrade
|
| Operating Cash Flow Growth | -7.89% | 7.91% | 18.19% | 24.77% | 7.73% | Upgrade
|
| Capital Expenditures | -1,112 | -856.89 | -1,451 | -1,555 | -2,042 | Upgrade
|
| Sale of Property, Plant & Equipment | 1.99 | 1.75 | 0.25 | 0.56 | - | Upgrade
|
| Investment in Securities | -520.08 | -718.69 | -184.76 | 395.22 | 88.64 | Upgrade
|
| Other Investing Activities | 29.95 | 27.73 | 55.85 | 41.4 | 1.07 | Upgrade
|
| Investing Cash Flow | -1,600 | -1,546 | -1,580 | -1,118 | -1,952 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | 50.99 | Upgrade
|
| Long-Term Debt Issued | - | - | - | - | 519.72 | Upgrade
|
| Total Debt Issued | - | - | - | - | 570.71 | Upgrade
|
| Short-Term Debt Repaid | - | - | -43.37 | - | - | Upgrade
|
| Long-Term Debt Repaid | -67.45 | -265.04 | -265.96 | -266.56 | -202.41 | Upgrade
|
| Total Debt Repaid | -67.45 | -265.04 | -309.33 | -266.56 | -202.41 | Upgrade
|
| Net Debt Issued (Repaid) | -67.45 | -265.04 | -309.33 | -266.56 | 368.3 | Upgrade
|
| Common Dividends Paid | -915.39 | -714.53 | -535.64 | -705.21 | -57.06 | Upgrade
|
| Other Financing Activities | -4.84 | -12.58 | -7.23 | -22.26 | - | Upgrade
|
| Financing Cash Flow | -987.68 | -992.15 | -852.19 | -994.02 | 311.24 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | - | - | -14.29 | - | Upgrade
|
| Net Cash Flow | -142.38 | 116.43 | 28.32 | -44.77 | 27.36 | Upgrade
|
| Free Cash Flow | 1,333 | 1,798 | 1,009 | 526.36 | -373.59 | Upgrade
|
| Free Cash Flow Growth | -25.83% | 78.14% | 91.72% | - | - | Upgrade
|
| Free Cash Flow Margin | 11.11% | 17.68% | 11.83% | 7.38% | -6.06% | Upgrade
|
| Free Cash Flow Per Share | 12.74 | 17.18 | 9.65 | 5.03 | -3.57 | Upgrade
|
| Cash Interest Paid | 6.33 | 26.5 | 39.58 | 53.15 | - | Upgrade
|
| Cash Income Tax Paid | 1,094 | 1,033 | 702.77 | 607.85 | 751.77 | Upgrade
|
| Levered Free Cash Flow | 698.14 | 1,178 | 505.95 | 188.91 | -831.9 | Upgrade
|
| Unlevered Free Cash Flow | 701.45 | 1,194 | 534.14 | 223.18 | -827.74 | Upgrade
|
| Change in Net Working Capital | 1,555 | 902.67 | 429.5 | 153.68 | 951.1 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.